Suggested Remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
Status In progress
Process STA 2018
ID number 1498

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
15 November 2018 - 13 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance